Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Parkinson's disease (PD) results primarily from the death of dopaminergic neurons in the substantia nigra. Current PD medications treat symptoms; none halt or retard dopaminergic neuron degeneration. The main obstacle to developing neuroprotective therapies is a limited understanding of the key molecular mechanisms that provoke neurodegeneration. The discovery of PD genes has led to the hypothesis that misfolding of proteins and dysfunction of the ubiquitin-proteasome pathway are pivotal to PD pathogenesis. Previously implicated culprits in PD neurodegeneration, mitochondrial dysfunction, and oxidative stress may also act in part by causing the accumulation of misfolded proteins, in addition to producing other deleterious events in dopaminergic neurons. Neurotoxin-based models have been important in elucidating the molecular cascade of cell death in dopaminergic neurons. PD models based on the manipulation of PD genes should prove valuable in elucidating important aspects of the disease, such as selective vulnerability of substantia nigra dopaminergic neurons to the degenerative process.

Parkinson's disease --- Chemotherapy. --- Antiparkinsonian agents --- Neurology & clinical neurophysiology

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Selegiline --- Parkinson's disease --- Antiparkinsonian agents --- Monoamine Oxidase Inhibitors --- Parkinson Disease --- Phenethylamines --- Testing --- Congresses. --- Chemotherapy --- Congresses. --- Testing --- Congresses. --- congresses. --- drug therapy --- congresses. --- therapeutic use --- congresses.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Parkinson’s disease is a common and devastating progressive disorder that primarily affects motor function. In this exciting and timely book, novel approaches to repairing the parkinsonian brain are described by some of the world’s leading scientists and clinicians in the field. Dealing with cutting-edge research, it covers several important topics including medical ethics, clinical trial design, stem cell biology, intracerebral transplantation, brain imaging, neurotrophic factors and neural regeneration. The comprehensive chapters are geared to an audience of neuroscientists, neurologists, neurosurgeons and anyone interested in how findings in the research laboratory can effectively be transferred to the clinic. Restorative therapies in Parkinson’s disease have pioneered translational research in the area of brain repair for close to three decades. This book clearly shows that research in Parkinson’s disease continues to play a leading role and can provide a model for how functional restoration might be achieved in several brain disorders in the future.

Parkinson's disease --- Antiparkinsonian agents. --- Treatment. --- Chemotherapy. --- Antiparkinson agents --- Antiparkinsonism agents --- Central nervous system depressants --- Antiparkinsonian agents --- Palsy, Shaking --- Paralysis agitans --- Parkinson disease --- Parkinsonism --- Shaking palsy --- Brain --- Extrapyramidal disorders --- Chemotherapy --- Diseases --- Neurosciences. --- Neurology. --- Neural sciences --- Neurological sciences --- Neuroscience --- Medical sciences --- Nervous system --- Medicine --- Neuropsychiatry --- Neurology .

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This e-book is a reference on Selegiline ((-)-Deprenyl) effects on the brain. Selegiline, described in thousands of research papers, is registered in over 60 countries. At present, more than one hundred preparations containing selegiline circulate in the global market under different brand names. They are widely used in the treatment of Parkinson's disease, Alzheimer's disease, major depression and as a geroprotective / anti-aging drug. ((-)-Deprenyl) selegiline, the first selective inhibitor of B-type MAO which, in contrast to the known MAO inhibitors, did not potentiate the effect of tyra

Depression, Mental. --- Brain --- Selegiline. --- Deprenalin --- Deprenil --- Deprenyl --- Antiparkinsonian agents --- Monoamine oxidase --- Phenethylamines --- Dejection --- Depression, Unipolar --- Depressive disorder --- Depressive psychoses --- Melancholia --- Mental depression --- Unipolar depression --- Affective disorders --- Neurasthenia --- Neuroses --- Manic-depressive illness --- Melancholy --- Sadness --- Aging. --- Inhibitors --- Bipolar disorder

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Far from celebrity media spotlight, ordinary individuals, many older and less advantaged, suffer the disabling pain of Parkinson's disease (PD), an illness whose progressive symptoms often mimic old age and cause mobility impairment, communication barriers, and social isolation. At the heart of With Shaking Hands is the account of elder Americans in rural Iowa who have been diagnosed with PD. With a focus on the impact of chronic illness on an aging population, Samantha Solimeo combines clear and accessible prose with qualitative and quantitative research to demonstrate how PD accelerates, mediates, and obscures patterns of aging. She explores how ideas of what to expect in older age influence and direct interpretations of one's body. This sensitive and groundbreaking work unites theories of disease with modern conceptions of the body in biological and social terms. PD, like other chronic disorders, presents a special case of embodiment which challenge our thinking about how such diseases should be researched and how they are experienced.

Health Services for the Aged. --- Caregivers --- Antiparkinson Agents. --- Aging --- Aged --- Parkinson Disease --- Medical anthropology. --- Parkinson's disease --- Medical care --- Medicine --- Anthropology --- Elderly --- Geriatrics --- Longevity --- Palsy, Shaking --- Paralysis agitans --- Parkinson disease --- Parkinsonism --- Shaking palsy --- Brain --- Extrapyramidal disorders --- Antiparkinson Drugs --- Antiparkinsonian Agents --- Antiparkinsonians --- Agents, Antiparkinson --- Agents, Antiparkinsonian --- Drugs, Antiparkinson --- Parasympatholytics --- Health Services for Aged --- Health Services for the Elderly --- Health Services, Geriatric --- Geriatric Health Services --- Geriatric Health Service --- Health Service, Geriatric --- Service, Geriatric Health --- Services, Geriatric Health --- Frail Elderly --- psychology. --- Anthropological aspects --- Diseases --- United States.